Comments
Loading...

Arbutus Biopharma

ABUSNASDAQ
Logo brought to you by Benzinga Data
$4.20
0.071.69%
Last update: 5:26 AM
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$9.00
Lowest Price Target1
$4.00
Consensus Price Target1
$6.00

Arbutus Biopharma (NASDAQ:ABUS) Stock, Analyst Ratings, Price Targets, Forecasts

Arbutus Biopharma Corp has a consensus price target of $6 based on the ratings of 5 analysts. The high is $9 issued by JMP Securities on November 8, 2021. The low is $4 issued by Chardan Capital on June 5, 2024. The 3 most-recent analyst ratings were released by Jefferies, JMP Securities, and HC Wainwright & Co. on September 5, 2024, August 2, 2024, and June 7, 2024, respectively. With an average price target of $5.67 between Jefferies, JMP Securities, and HC Wainwright & Co., there's an implied 34.92% upside for Arbutus Biopharma Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Apr
0
0
0
0
May
0
0
0
0
Jun
0
0
0
0
Aug
0
0
0
0
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Jefferies
JMP Securities
HC Wainwright & Co.
Chardan Capital
JMP Securities

1calculated from analyst ratings

Analyst Ratings for Arbutus Biopharma

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Arbutus Biopharma (ABUS) stock?

A

The latest price target for Arbutus Biopharma (NASDAQ:ABUS) was reported by Jefferies on September 5, 2024. The analyst firm set a price target for $7.00 expecting ABUS to rise to within 12 months (a possible 66.67% upside). 9 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Arbutus Biopharma (ABUS)?

A

The latest analyst rating for Arbutus Biopharma (NASDAQ:ABUS) was provided by Jefferies, and Arbutus Biopharma maintained their buy rating.

Q

When was the last upgrade for Arbutus Biopharma (ABUS)?

A

The last upgrade for Arbutus Biopharma Corp happened on February 2, 2022 when Jefferies raised their price target to $5. Jefferies previously had a hold for Arbutus Biopharma Corp.

Q

When was the last downgrade for Arbutus Biopharma (ABUS)?

A

There is no last downgrade for Arbutus Biopharma.

Q

When is the next analyst rating going to be posted or updated for Arbutus Biopharma (ABUS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arbutus Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arbutus Biopharma was filed on September 5, 2024 so you should expect the next rating to be made available sometime around September 5, 2025.

Q

Is the Analyst Rating Arbutus Biopharma (ABUS) correct?

A

While ratings are subjective and will change, the latest Arbutus Biopharma (ABUS) rating was a maintained with a price target of $5.00 to $7.00. The current price Arbutus Biopharma (ABUS) is trading at is $4.20, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.